Trial Profile

Real Life Assessment of the Association and Its Determinants Between Side Effects and Plasmatic Concentrations of Two Protein Kinase Inhibitors: Ibrutinib (IMBRUVICA®) and Idelalisib (ZYDELIG®) in Hematological Malignancies Treatment

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 24 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Idelalisib (Primary)
Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
Focus Adverse reactions
Acronyms PK-e3i trial

18 Feb 2025 Results of Ibrutinib pharmacokinetics in B-lymphoproliferative disorders that discloses exposure-related incidence of hypertension, published in the Journal of Hypertension.
04 Feb 2021 Results of Population PK-PD modelling of circulating lymphocyte dynamics in chronic lymphocytic leukemia patients using data from this trial published in the Clinical Pharmacology and Therapeutics
24 Dec 2020 Status changed from discontinued to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com